Ready-to-Use Pre-Filled Syringe Formulations
•10 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (10)
%
| Company | Market Cap | Price |
|---|---|---|
|
Ready-to-use pre-filled syringe formulations tied to injectable therapies and auto-injector delivery formats.
|
$458.89B |
$190.72
-0.67%
|
|
Ready-to-Use Pre-Filled Syringe Formulations used for delivering VYVGART Hytrulo.
|
$47.65B |
$796.92
-0.76%
|
|
RTU pre-filled syringe formulations are a key product/solution, aligning with Ready-to-Use syringe formats.
|
$7.22B |
$23.85
-0.58%
|
|
Directly tied to Akero's lead product candidate EFX being developed as a ready-to-use pre-filled syringe formulation for administration.
|
$4.30B |
$53.88
-0.39%
|
|
Ready-to-Use Pre-Filled Syringe Formulations tied to 505(b)(2) injectables in the pipeline.
|
$3.12B |
$9.97
-3.11%
|
|
Manufacturing for barzolvolimab includes pre-filled syringe formulations, indicating readiness in delivery device/formulation.
|
$1.74B |
$26.14
+1.79%
|
|
XeriSol and XeriJect enable ready-to-use injectable formulations, mapping to the Ready-to-Use Pre-Filled Syringe Formulations tag.
|
$1.28B |
$7.99
-2.44%
|
|
Cryopreserved, ready-to-administer thaw-and-inject formulation aligns with Ready-to-Use Pre-Filled Syringe Formulations as a delivery format for injectables.
|
$385.92M |
$1.69
-1.74%
|
|
The company fills ready-to-use pre-filled syringe formulations, aligning with Ready-to-Use Pre-Filled Syringe Formulations.
|
$240.66M |
$6.50
-2.40%
|
|
Ready-to-use pre-filled syringe candidates (Fedsyra and phenylephrine) form part of Talphera's drug delivery strategy.
|
$25.22M |
$1.23
-3.15%
|
Loading industry metrics...
Loading comparison data...
